Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Research & Discovery » Proteomics & Protein Research » Confident of Market Turnaround, MDS Proteomics Plans IPO for 2002

Confident of Market Turnaround, MDS Proteomics Plans IPO for 2002

Dec 17, 2001
Premium

MDS Proteomics plans to go through with an initial public offering next year to acquire additional funding, the company’s new CFO said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Free of Influence

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

Avoiding the MARCH1 to 1-Mar Change

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

Nature Papers Reveal Tuatara Genome, Cell Populations Involved in Lupus

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

Overlooked Expertise

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.

Sep
09
Featured Webinar

Spatially Resolved Transcriptomics: The Landscape of Tools for Spatial Gene Expression

Sponsored by
10x Genomics

Recent advances in spatially resolved transcriptomics have greatly expanded the knowledge of complex multicellular biological systems. 

What's Popular?

In Proteomics & Protein Research

  1. Quanterix Q2 Revenues Down 3 Percent, Beating Wall Street Estimate

  2. Fluidigm, De Novo Software Ink Distribution Deal

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.